On this page you will find our recommendations sorted by BNF chapter.

Appraisal Reports are available to stakeholders on request.

Where a decision is >24 months old; these are highlighted in red. If you are a clinician working within the NTAG region and would like to prioritise an old decision for re-review please contact the professional secretary on nuth.nyrdtc.rxsupp@nhs.net

Title Documents Decision Date

Updated

07/06/2022
Budesonide orodispersible for maintenance treatment of eosinophilic oesophagitis Recommendation Recommended as an option 07/06/2022
Infliximab biosimilars See Musculoskeletal and joint diseases recommendations Recommended as an option 02/06/2015
Infliximab Subcutaneous (Remsima®) Musculoskeletal and joint diseases recommendations Recommended as an option during Covid-19 Pandemic. 22/02/2022
Leukapheresis with Adacolumn™ for Inflammatory Bowel Disease (NETAG) Recommendation Not recommended 18/01/2011

Updated

31/01/2023
Transanal Irrigation Systems (TAIs) for neurogenic bowel dysfunction, chronic constipation, and chronic faecal incontinence Recommended for restricted use. Recommended as per NTAG Decision Summary in NENC Medicines Committee Recommendations from December 2022 https://northeastnorthcumbria.nhs.uk/about-us/publications/medicines-committee/ 15/11/2022